For: | Sakaguchi M, Takao M, Ohyama Y, Oka H, Yamashita H, Fukuchi T, Ashida K, Murotani M, Murotani M, Majima K, Morikawa H, Hashimoto T, Kiyota K, Esaki H, Amemoto K, Isowa G, Takao F. Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia. World J Gastroenterol 2012; 18(13): 1517-1524 [PMID: 22509084 DOI: 10.3748/wjg.v18.i13.1517] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v18/i13/1517.htm |
Number | Citing Articles |
1 |
T.M. Vinaya, B.S. Aravind, David Sibbritt, Tripathy Tapasbrata, S. Shivakumar. The use of Benincasa hispida for the treatment of uninvestigated dyspepsia: Preliminary results of a non-randomised open label pilot clinical trial. Advances in Integrative Medicine 2015; 2(3): 130 doi: 10.1016/j.aimed.2015.09.003
|
2 |
Qian Huang, Shaopeng Zheng, Ting Cai, Suxin Zhang, Qian Su, Fen Wang. Factors associated with mood disorders and the efficacy of the targeted treatment of functional dyspepsia: A randomized clinical trial. Frontiers in Medicine 2022; 9 doi: 10.3389/fmed.2022.859661
|
3 |
Maria Ines Pinto-Sanchez, Yuhong Yuan, Premysl Bercik, Paul Moayyedi. Proton pump inhibitors for functional dyspepsia. Cochrane Database of Systematic Reviews 2017; doi: 10.1002/14651858.CD011194.pub2
|
4 |
Maria Ines Pinto-Sanchez, Yuhong Yuan, Ahmed Hassan, Premysl Bercik, Paul Moayyedi. Proton pump inhibitors for functional dyspepsia. Cochrane Database of Systematic Reviews 2017; 2018(3) doi: 10.1002/14651858.CD011194.pub3
|
5 |
Kwang Jae Lee. The Usefulness of Symptom-based Subtypes of Functional Dyspepsia for Predicting Underlying Pathophysiologic Mechanisms and Choosing Appropriate Therapeutic Agents. Journal of Neurogastroenterology and Motility 2021; 27(3): 326 doi: 10.5056/jnm21042
|
6 |
Toru Arai, Yoshikazu Inoue, Yumiko Sasaki, Kazunobu Tachibana, Keiko Nakao, Chikatoshi Sugimoto, Tomohisa Okuma, Masanori Akira, Masanori Kitaichi, Seiji Hayashi. Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respiratory Investigation 2014; 52(2): 136 doi: 10.1016/j.resinv.2013.09.002
|
7 |
Ronnell Regidor. H2RBs vs PPIs part 2: histamine-2 receptor blockers as a first-line agent for peptic ulcer disease prophylaxis. Gastrointestinal Nursing 2013; 11(6): 25 doi: 10.12968/gasn.2013.11.6.25
|
8 |
Klaus Bielefeldt, Ashok Tuteja, Salman Nusrat. Disorders of gastrointestinal hypomotility. F1000Research 2016; 5: 1897 doi: 10.12688/f1000research.8658.1
|
9 |
R. Carmona-Sánchez, O. Gómez-Escudero, M. Zavala-Solares, M.V. Bielsa-Fernández, E. Coss-Adame, A.I. Hernández-Guerrero, F. Huerta-Iga, M.E. Icaza-Chávez, M.A. Lira-Pedrín, J.A. Lizárraga-López, A. López-Colombo, A. Noble-Lugo, J. Pérez-Manauta, R.H. Raña-Garibay, J.M. Remes-Troche, J.L. Tamayo, L.F. Uscanga, F. Zamarripa-Dorsey, M.A. Valdovinos Díaz, J.A. Velarde-Ruiz Velasco. Mexican consensus on dyspepsia. Revista de Gastroenterología de México (English Edition) 2017; 82(4): 309 doi: 10.1016/j.rgmxen.2017.01.004
|
10 |
Annelies Geeraerts, Brecht Van Houtte, Egbert Clevers, Hannelore Geysen, Tim Vanuytsel, Jan Tack, Ans Pauwels. Gastroesophageal Reflux Disease—Functional Dyspepsia Overlap: Do Birds of a Feather Flock Together?. American Journal of Gastroenterology 2020; 115(8): 1167 doi: 10.14309/ajg.0000000000000619
|
11 |
R. Carmona-Sánchez, O. Gómez-Escudero, M. Zavala-Solares, M.V. Bielsa-Fernández, E. Coss-Adame, A.I. Hernández-Guerrero, F. Huerta-Iga, M.E. Icaza-Chávez, M.A. Lira-Pedrín, J.A. Lizárraga-López, A. López-Colombo, A. Noble-Lugo, J. Pérez-Manauta, R.H. Raña-Garibay, J.M. Remes-Troche, J.L. Tamayo, L.F. Uscanga, F. Zamarripa-Dorsey, M.A. Valdovinos Díaz, J.A. Velarde-Ruiz Velasco. Consenso mexicano sobre la dispepsia. Revista de Gastroenterología de México 2017; 82(4): 309 doi: 10.1016/j.rgmx.2017.01.001
|
12 |
L. Gottschalk, V. Andresen, P. Layer. Reizdarmsyndrom und funktionelle Dyspepsie. Der Internist 2022; 63(1): 51 doi: 10.1007/s00108-021-01218-3
|
13 |
Fei Liu, Yanjun Xu, Li Wang, Xifeng Ma, Zhen Zhang, Xiaomei Zhuang. Combined contributions of cytochrome P450s (CYPs) and non-enzymatic metabolism in the in vitro biotransformation of anaprazole, a novel proton pump inhibitor. Naunyn-Schmiedeberg's Archives of Pharmacology 2023; 396(8): 1759 doi: 10.1007/s00210-023-02415-7
|
14 |
Jutta Keller, Arne Kandulski. Funktionelle Magen-Darm-Erkrankungen. Die Gastroenterologie 2023; 18(6): 469 doi: 10.1007/s11377-023-00734-y
|
15 |
Ronnell Regidor. Histamine-2 receptor blockers vs proton pump inhibitors part 1: a literature review. Gastrointestinal Nursing 2013; 11(5): 30 doi: 10.12968/gasn.2013.11.5.30
|
16 |
Michael Camilleri, Vincenzo Stanghellini. Current management strategies and emerging treatments for functional dyspepsia. Nature Reviews Gastroenterology & Hepatology 2013; 10(3): 187 doi: 10.1038/nrgastro.2013.11
|
17 |
Yoshikazu Kinoshita, Hiroto Miwa, Katsuyuki Sanada, Koji Miyata, Ken Haruma. Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia. Journal of Gastroenterology 2014; 49(4): 628 doi: 10.1007/s00535-013-0812-3
|
18 |
P. S. Nishtala, L. Soo. Proton pump inhibitors utilisation in older people in New Zealand from 2005 to 2013. Internal Medicine Journal 2015; 45(6): 624 doi: 10.1111/imj.12757
|